---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-088738"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-19T00:35:13.674052+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lineage reports OpRegen 36-month data: +9 ETDRS letters in extensive-coverage GA patients

## Summary
- Mean BCVA gain of +6.2 letters (n=10) persisting through 36 months vs. +5.5 at 24 months.
- Patients with extensive bleb coverage (n=5) showed mean +9.0 letters at 36 months vs. +7.4 at 24 months.
- Retinal structure improvements (RPEDC, ELM) on OCT sustained in treated eyes; untreated fellow eyes declined.
- Phase 2a GAlette study enrolling (NCT05626114) testing proprietary surgical delivery devices.
- CEO states data challenges view that GA causes irreversible damage; effects durable after single injection.

## SEC filing metadata
- accession: 0000950170-25-088738
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017025088738/0000950170-25-088738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017025088738/lctx-20250623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-088738
- JSON: https://secwatch.observer/filing/0000950170-25-088738.json
- Plain text: https://secwatch.observer/filing/0000950170-25-088738.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.